Despite resubmitting after an initial complete response letter (CRL) due to manufacturing issues, the combination therapy ...

IntroductionProgrammed cell death protein 1 (PD-1) and its ligand, PD-L1, are crucial immune checkpoints that regulate the ...

With the rising adoption of checkpoint inhibitors and combination therapies, BAVENCIO's market growth is driven by expanding indications and strategic partnerships. However, competition from ...

Phase III MATTERHORN trial data show a statistically significant and clinically meaningful improvement in event-free survival for patients with resectable gastric and gastroesophageal junction cancer ...

AstraZeneca’s Imfinzi is under regulatory review in China, Japan and other countries. Credit: © AstraZeneca 2025. AstraZeneca’s Imfinzi (durvalumab) plus ...

Background Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality. The combination of tremelimumab and durvalumab is now a standard treatment option for advanced HCC. Objective ...

Astrazeneca Pharma India added 2.08% to Rs 6846.10 after the company has received permission from the Central Drugs Standard Control Organisation (CDSCO) to import for sale and distribution of ...

CKPT's main drug of focus at this time is cosibelimab, an antibody targeting PD-L1 (similar to approved drugs like durvalumab, atezolizumab, and avelumab). They hope that by maintaining a ...

AstraZeneca (NASDAQ:AZN) has announced that its drug Imfinzi (durvalumab), in combination with chemotherapy, has been recommended for approval in the European Union. The recommendation by the ...

1Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany. 2Medical Faculty, University Duisburg-Essen, Essen, Germany. 3National Center of Tumor Diseases ...

Cancer screening is conceptually a good approach for reducing the mortality of lung cancer. So far, none of the tested approaches have improved the specific mortality rate. Further research is ...

Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.3 ...